In 2002, a group of doctors and entrepreneurs in Silicon Valley, California, launched a start-up with the aim of exploring peptide applications in biologics for various therapeutic purposes. Their mission was to use peptides as a medium for delivering biologics, often large molecules, through the skin.
Initially, their focus was on combining botulinum toxin type A, the active ingredient in DAXXIFY®, with a peptide to test its topical application for treating crow’s feet wrinkles. However, scientific exploration revealed that the optimal method of administering the formulation was via injection. This led to multiple clinical studies being conducted to identify the right dosage for an injectable product to treat frown lines.
DAXXIFY® showed an average longevity of 6 months, even lasting up to 9 months for some individuals, in clinical trials.# It’s distinguished as the only treatment of its kind that incorporates a peptide.
#Clinical studies showed that at least 50% of patients had no or minor frown lines 6 months post-treatment. Between 3% and 5% of patients in these studies still had no or minor frown lines 9 months post-treatment. Further safety studies indicated that between 5% and 17% of patients still showed noticeable improvements 9 months later.